Dear SMA Community, While 2020 did not pan out as we had expected, Cure SMA remains extremely optimistic about the future for our community in 2021 and beyond. Here are the reasons why: Research and Treatment The research Cure SMA funds continues to expand our knowledge of SMA and deliver treatment opportunities, as reflected in […]
Cure SMA’s New Year Letter for 2021 Read More »
Dear SMA Community, As 2020 draws to a close, we want to provide an overview of our recent work in the community over the fourth quarter and updates related to clinical studies of Evrysdi™ (risdiplam), which was approved earlier this year for the treatment of spinal muscular atrophy (SMA) in people 2 months of age
Genentech End-of-Year Community Statement Read More »
Below we have provided an update from Biogen regarding the status of its DEVOTE clinical trial. For more information about SPINRAZA (nusinersen), visit https://www.curesma.org/spinraza/. ++++++++++++++++++++ Biogen’s DEVOTE study is designed to evaluate the safety, tolerability, and potential for even greater efficacy of SPINRAZA when administered at a higher dose than currently approved for the treatment
Biogen Provides SMA Community Update on DEVOTE Study Read More »
During our past fiscal year—from July 1, 2019 to June 30, 2020—Cure SMA funded more than $9 million in new and ongoing research and care initiatives. This money will be used strategically to help accelerate research and ensure we are developing treatments and protocols for all types, ages, and stages of spinal muscular atrophy (SMA).
Cure SMA Funds Over $9 Million in New and Ongoing Research in FY20 Read More »
To the full spinal muscular atrophy (SMA) community, we want you to know that Cure SMA is continuing to support you with information and resources related to the COVID-19 pandemic. The following frequently asked questions (FAQs) are designed to help address key concerns expressed by members of the SMA community about COVID-19 vaccination and provide
Answering Questions about COVID-19 Vaccination and SMA Read More »
Dear SMA Community, Although this year has brought with it many challenges, the SMA community continues to demonstrate its strength and resilience. Cure SMA remains committed to bringing you the information, resources, and support you need as we continue to navigate the COVID-19 pandemic. Last week, the Advisory Committee on Immunization Practices (ACIP)—a U.S. Centers
Cure SMA Shares Perspective on COVID-19 Vaccination Read More »
Dear Members of the SMA Community, As we celebrate National Family Caregivers Month this November, Biogen acknowledges the vital role caregivers have in our society, including within our spinal muscular atrophy (SMA) community. We also recognize that caregivers need our support more than ever. Caregivers in the SMA community face an especially unique set of
Biogen SMA Q4 2020 Community Statement Read More »
Cure SMA is excited to be announcing—along with support from Biogen—the launch of two new programs for adults with SMA. First, we will test your knowledge of random (and useless) facts with an Adults with SMA Virtual Trivia Night. Then, in the coming months, we will begin hosting an Adults with SMA Virtual Book Club.
Cure SMA Announces Two New Virtual Programs for Adults with SMA Read More »
Contributors: Dr. Mary Schroth and Dr. Robert Graham Influenza (or flu) is a serious respiratory infection, and people of any age can get it. Since 2010, the Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in between 140,000 and 810,000 hospitalizations each year and 12,000 to 61,000 deaths. There is always
Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced 6-month interim results from their clinical program for its product candidate SRK-015, a treatment being developed for spinal muscular atrophy (SMA). SRK-015 is a highly selective inhibitor of latent myostatin and
